NAMS

NewAmsterdam Pharma Company N.V.
CAPPED RATING

NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP), which has been clinically shown to reduce low-density lipoprotein cholesterol (LDL-C) while at the same time substantially increase high-density lipoprotein cholesterol (HDL-C). The company was founded in 2019 and is based in Naarden, the Netherlands.

NewAmsterdam Pharma Company N.V. (NAMS) is rated C (2.4/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Profitability (B); its weakest is Momentum (D+). The rating has held at C for 7 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.4 / 5.0
C
Value
C
Factor Score 2.4 / 5.0
Growth
C-
Factor Score 1.9 / 5.0
Profitability
B
Factor Score 3.5 / 5.0
Momentum
D+
Factor Score 1.7 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -9.7
EV / EBITDA -7.6
Rev Growth YoY N/M
Gross Margin N/M
Price Return 3M -26.0%
Price Return 12M -49.9%
Catalyst Signal 0.00
Market Cap $2.4B
TTM Revenue $25.9M
Price / Sales 92.3
ROE -30.2%

Historical Factor Score Progression

Held C for 7 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-13 C (2.4) C- (1.9) B (3.5) D+ (1.7) C+ (2.6) C (2.4)
2026-11-06 D (1.2) C+ (2.5) B (3.4) D+ (1.7) C+ (2.7) C (2.3)
2026-10-30 D- (1.0) C+ (2.5) B (3.4) C- (2.0) C+ (2.7) C (2.3)
2026-10-23 D- (0.9) C+ (2.5) B (3.4) D+ (1.6) C+ (2.6) C (2.2)
2026-10-16 D- (1.0) C+ (2.5) B (3.4) D (1.4) C+ (2.6) C (2.2)
Page 1 of 5